Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Urogen Pharma (NASDAQ:URGN), indicating ongoing concerns about the company's performance.
• Urogen recently reported a quarterly loss of ($1.05) EPS, missing analysts' expectations while achieving revenues of $24.22 million.
• Insiders have been actively selling their shares, with General Counsel Jason Drew Smith selling 1,520 shares for approximately $29,047, reflecting a decrease in ownership percentage.

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

URGN has been the topic of a number of other reports. Wall Street Zen upgraded Urogen Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Piper Sandler assumed coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 price target for the company. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. Guggenheim reissued a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $32.00.

Urogen Pharma Price Performance

Shares of URGN stock traded up $0.49 during trading hours on Wednesday, reaching $17.33. The stock had a trading volume of 939,450 shares, compared to its average volume of 1,191,119. The stock's fifty day simple moving average is $18.89 and its 200 day simple moving average is $13.78. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, sell-side analysts predict that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares of the company's stock, valued at approximately $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider owned 148,229 shares of the company's stock, valued at $2,622,171.01. This represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,062 shares of company stock valued at $465,115 in the last quarter. Corporate insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Urogen Pharma during the 1st quarter valued at $1,028,000. Rhumbline Advisers increased its position in shares of Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after buying an additional 2,196 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Urogen Pharma during the first quarter valued at about $194,000. Parkman Healthcare Partners LLC lifted its holdings in Urogen Pharma by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock worth $4,348,000 after buying an additional 23,292 shares during the period. Finally, XTX Topco Ltd lifted its holdings in Urogen Pharma by 39.3% in the first quarter. XTX Topco Ltd now owns 25,967 shares of the company's stock worth $287,000 after buying an additional 7,326 shares during the period. 91.29% of the stock is currently owned by institutional investors.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.